2,3,5-triisopropylthiophene

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 噻吩类
• 英文名称: 2,3,5-triisopropylthiophene
• 英文别名: 2,3,5-triisopropyl-thiophene；2,3,5-Triisopropyl-thiophen；2,3,5-Tri(propan-2-yl)thiophene
• 化学式: C₁₃H₂₂S
• 分子量: 210.384
• InChiKey: ILTRNPRCGBQUMM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  14
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.69
• 拓扑面积：
  28.2
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  2,3,5-triisopropylthiophene 在 AlSi 作用下， 生成 噻吩 、 2-异丙基噻吩
  参考文献：
  名称：

  Mashkina; Chernov, Petroleum Chemistry, 2005, vol. 45, # 3, p. 209 - 215

  摘要：

  DOI：
• 作为产物：
  描述：

  2-异丙基噻吩 、 三聚丙烯 在 硫酸 作用下， 生成 2,3,5-triisopropylthiophene
  参考文献：
  名称：

  Sulfuric acid alkylation of thiophene compounds

  摘要：

  公开号：

  US02529298A1

文献信息

• [EN] SULFONYLUREA DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONYLURÉE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249664A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式(I)化合物及其前药、药用可接受盐、药物组合物、使用方法和制备方法。所公开的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗炎症、自身炎症和自身免疫疾病以及癌症等炎症小体活性涉及的疾病。
• [EN] SULFONAMIDE DERIVATIVES AND USES THEREOF<br/>[FR] DÉRIVÉS DE SULFONAMIDE ET LEURS UTILISATIONS
  申请人：NODTHERA LTD

  公开号：WO2020249669A1

  公开（公告）日：2020-12-17

  The present disclosure relates to compounds of Formula (I) or (II): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

  本公开涉及式（I）或（II）的化合物，以及它们的前药、药用盐、药物组合物、使用方法和制备方法。本文披露的化合物可用于通过抑制炎症小体来抑制IL-1家族细胞因子的成熟，并可用于治疗涉及炎症小体活性的疾病，如炎症性、自身免疫性和自身免疫性疾病以及癌症。
• Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
  申请人：Rodgers D. James

  公开号：US20070135461A1

  公开（公告）日：2007-06-14

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可以调节雅努斯激酶的活性，并且在治疗与雅努斯激酶活性相关的疾病中具有用处，例如免疫相关疾病、皮肤疾病、髓增生性疾病、癌症和其他疾病。
• JANUS KINASE INHIBITORS FOR TREATMENT OF DRY EYE AND OTHER EYE RELATED DISEASES
  申请人：Incyte Corporation

  公开号：US20170087158A1

  公开（公告）日：2017-03-30

  The present application relates to Janus kinase (JAK) inhibitors, including 3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile, for the treatment of a dry eye disorder or ameliorating a particular symptom of a dry eye disorder, such as eye discomfort, visual disturbance, tear film instability, tear hyperosmolarity, and inflammation of the ocular surface, as well as kits and compositions, including topical compositions, related thereto.

  本申请涉及Janus激酶（JAK）抑制剂，包括3-环戊基-3- [4-（7H-吡咯[2,3-d]嘧啶-4-基）-1H-吡唑-1-基]丙腈，用于治疗干眼症或改善干眼症的特定症状，如眼部不适，视觉障碍，泪膜不稳定，泪液高渗性和眼表炎症，以及相关的套件和组合物，包括局部组合物。
• HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090181959A1

  公开（公告）日：2009-07-16

  The present invention provides heteroaryl substituted pyrrolo[2,3-b]pyridines and heteroaryl substituted pyrrolo[2,3-b]pyrimidines that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.

  本发明提供了杂环取代的吡咯并[2,3-b]吡啶和杂环取代的吡咯并[2,3-b]嘧啶，可调节Janus激酶的活性，并可用于治疗与Janus激酶活性相关的疾病，包括免疫相关疾病、皮肤疾病、髓系增生性疾病、癌症和其他疾病。